Latest Instil Bio News & Updates

See the latest news and media coverage for Instil Bio. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Instil Bio

Biotechnology company advancing innovative therapeutic opportunities

instilbio.com
Company type
Public company
Number of employees
10–50
Industry
Pharmaceuticals

Last updated

Latest news about Instil Bio

In short: Instil Bio discontinued its lead TIL and AXN-2510 programs, cut 60% of staff, and pivoted to acquisitions; Q2 cash stood at $69.9M.

Company announcements

Instil Bio

Instil Bio holds 2026 annual meeting

Stockholders elected two directors and ratified the independent auditor. The company reported high shareholder participation rates for both proposals.

Instil Bio

Instil Bio discontinues AXN-2510 and ends ImmuneOnco collaboration

Under the termination, rights revert to ImmuneOnco, and Axion winds down clinical development of AXN-2510, an investigational therapy.

Unlock all announcements with a

Media coverage

Barron's

Instil Bio Inc.

Instil Bio Inc. research and ratings by Barron's. View TIL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

FierceBiotech

Instil Bio takes the ax to its lead asset, cutting 60% of its staff in the process

Instil Bio is calling it quits on its lead tumor-infiltrating lymphocyte therapy and four corresponding programs, a major overhaul of the company's priorities that's resulting...

Unlock all articles with a

Never miss news about Instil Bio

Track Instil Bio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Instil Bio competitors & trending companies

Browse news for competitors to Instil Bio and other trending companies.